Gufic Biosciences · NSE: GUFICBIO · BSE: 509079
Q2 FY26 results · Jul–Sep 2025
Gufic Biosciences reported revenue from operations of ₹237.05 crore (up 16.1% from Q2 FY25) and net profit of ₹16.82 crore (down 22.7% from Q2 FY25) for Q2 FY26 (Jul–Sep 2025), on a consolidated basis.
| Item | Q2 FY26 | Q2 FY25 | YoY | Q1 FY26 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 237.05 | 204.18 | +16.1% | 223.72 | +6.0% |
| Other income | 2.12 | 0.11 | 19x | 0.93 | +128.7% |
| Total income | 239.17 | 204.29 | +17.1% | 224.65 | +6.5% |
| Profit before tax | 22.60 | 29.25 | −22.7% | 17.27 | +30.9% |
| Net profit for the period | 16.82 | 21.77 | −22.7% | 13.07 | +28.7% |
| EPS, basic (₹) | 1.68 | 2.17 | −22.6% | 1.30 | +29.2% |
| Net margin (%) | 7.1 | 10.7 | 5.8 |
| Item | Q2 FY26 | Q2 FY25 | YoY | Q1 FY26 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 230.42 | 204.18 | +12.9% | 226.91 | +1.5% |
| Other income | 2.09 | 0.11 | 18x | 0.89 | +133.8% |
| Total income | 232.51 | 204.29 | +13.8% | 227.81 | +2.1% |
| Profit before tax | 20.53 | 29.26 | −29.8% | 16.28 | +26.1% |
| Net profit for the period | 14.94 | 21.78 | −31.4% | 12.07 | +23.7% |
| EPS, basic (₹) | 1.49 | 2.17 | −31.3% | 1.20 | +24.2% |
| Net margin (%) | 6.5 | 10.7 | 5.3 |
Consolidated
- Filed with BSE
- 14 Nov 2025, 20:31 IST
- Board meeting
- 14 Nov 2025
- Period
- 01 Jul 2025 to 30 Sep 2025
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 14 Nov 2025, 20:31 IST
- Board meeting
- 14 Nov 2025
- Period
- 01 Jul 2025 to 30 Sep 2025
- Review status
- Unaudited
- Source
- XBRL filing on BSE